Nice analysis there Straynut,.....
Am still not sure if/when NNVC will see >$100/share - but suspect that if it does reach those lofty quantities it won't be for at least a few years. Just too much lost ground to be made up and not enough certainty of sufficient revenue sources to drive a gain to those levels (yet).
Am among those 'tough as nails' retail investors who have been through the ringer the last few years,... and know I won't be selling anything merely on a 2x or 3x gain from today's levels.
In fact - it is likely I'll keep on adding opportunistically with 'only' a 2x -3x gain back to the levels we were seeing c2013-2014. Have been adding shares aggressively (at least as aggressively as I ever do) during the downslide late 2014-present anyway - so the old cost-average isn't bad relative to current shareprices.
In my 'pie in the sky' scenario for NNVC post revenue generation I would love to see NNVC stay independent (rather than a straight up buy out) and become a steady growing, dividend paying mid-cap pharma.
But suspect that a buyout at some significant premium for shareholders after one of the drug candidates hits the market is the more likely scenario with the relative ages of Dr. Seymour, Dr. Bionuk and others attached to the company. Think they are more likely to want to cash out and enjoy their big-time wealth than to want to build NNVC into some big-time player.
News 
Market Data 
Discover 
